$4.70
0.173.75%
At close: Jun 18, 5:00 PM EST
$4.65
-0.05-1.06%
After Hours: Jun 16, 8:46 AM EST
CNS Pharmaceuticals Inc Analyst Ratings
CNSPNASDAQ
CNS Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:CNSP | Benzinga
CNS Pharmaceuticals Inc has a consensus price target of $20 based on the ratings of 1 analysts. The high is $20 issued by Maxim Group on September 12, 2025. The low is $20 issued by Maxim Group on September 12, 2025. The 2 most-recent analyst ratings were released by Maxim Group on September 12, 2025 and September 10, 2024, respectively. With an average price target of $10.25 between Maxim Group, there's an implied 120.43% upside for CNS Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
1calculated from analyst ratings
Analyst Ratings for CNS Pharmaceuticals
Loading calendar...
FAQ
What is the target price for CNS Pharmaceuticals (CNSP) stock?
The latest price target for CNS Pharmaceuticals (NASDAQ:CNSP) was reported by Maxim Group on September 12, 2025. The analyst firm set a price target for $20.00 expecting CNSP to rise to within 12 months (a possible 330.11% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CNS Pharmaceuticals (CNSP)?
The latest analyst rating for CNS Pharmaceuticals (NASDAQ:CNSP) was provided by Maxim Group, and CNS Pharmaceuticals upgraded their buy rating.
When was the last upgrade for CNS Pharmaceuticals (CNSP)?
The last upgrade for CNS Pharmaceuticals Inc happened on September 12, 2025 when Maxim Group raised their price target to $20. Maxim Group previously had a hold for CNS Pharmaceuticals Inc.
When was the last downgrade for CNS Pharmaceuticals (CNSP)?
The last downgrade for CNS Pharmaceuticals Inc happened on March 25, 2025 when Maxim Group changed their price target from N/A to N/A for CNS Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for CNS Pharmaceuticals (CNSP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CNS Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CNS Pharmaceuticals was filed on September 12, 2025 so you should expect the next rating to be made available sometime around September 12, 2026.
Is the Analyst Rating CNS Pharmaceuticals (CNSP) correct?
While ratings are subjective and will change, the latest CNS Pharmaceuticals (CNSP) rating was a upgraded with a price target of $0.00 to $20.00. The current price CNS Pharmaceuticals (CNSP) is trading at is $4.65, which is within the analyst’s predicted range.
